Biosimilar Newsletter Archive

1. 08.06.26 -- Achieving Annex 1 Compliance In Sterile Manufacturing 8/6/2026
   08/06/26
2. 07.30.26 -- FDA Explains How To Respond To Form 483 Observations 7/30/2026
   07/30/26 Biosimilar Development Newsletter
3. 07.23.26 -- Solving Glycoengineering Challenges Could Begin At The Cell Line 7/23/2026
   07/23/26
4. 07.16.26 -- Is Your AI Model Trustworthy & Credible In GMP Processes 7/16/2026
   07/16/26 Biosimilar Development Newsletter
5. 07.09.26 -- Affinity Membranes Are Moving Closer To Commercial Reality 7/9/2026
   07/09/26 Biosimilar Development Newsletter
6. 07.02.26 -- What Reliance, Annex 1, And AI Mean For The Future Of GMP 7/2/2026
   07/02/26 Biosimilar Development Newsletter
7. 06.25.26 -- Smarter risk management for single-use and filtration systems. 6/25/2026

   06/25/26 Biosimilar Development Newsletter

8. 06.25.26 -- What To Do About Process Drift In Your Biosimilar's Reference Product 6/25/2026
   06/25/26 Biosimilar Development Newsletter
9. 06.18.26 -- Reduce mAb Aggregates: Practical Strategies 6/18/2026

   06/18/26 Biosimilar Development Newsletter

10. 06.18.26 -- Will FDA's One-Day Inspection Pilot Stand The Test Of Time? 6/18/2026
    06/18/26 Biosimilar Development Newsletter